The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer: 2-Year update data.
 
Jiafu Ji
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche; Sanofi
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); CANbridge Pharmaceuticals (Inst); Jacobio (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)
 
Ziyu Li
No Relationships to Disclose
 
Xiangyu Gao
No Relationships to Disclose
 
Ke Ji
No Relationships to Disclose
 
Ye Chen
No Relationships to Disclose
 
Nong Xu
No Relationships to Disclose
 
Tianshu Liu
No Relationships to Disclose
 
Nong Yang
No Relationships to Disclose
 
Haijun Zhong
No Relationships to Disclose
 
Changzheng Li
No Relationships to Disclose
 
Zengqing Guo
No Relationships to Disclose
 
Qingxia Fan
No Relationships to Disclose
 
Xiaoyan Lin
No Relationships to Disclose
 
Zhifang Yao
Employment - Akeso Biopharma
 
Wei Liu
Employment - Akeso Biopharma
 
Zhongmin Maxwell Wang
Employment - Akeso Biopharma
 
Baiyong Li
Employment - Akeso Biopharma
 
Yu Xia
Employment - Akeso Biopharma